载药微球化疗栓塞治疗在肝癌肝移植术前应用的现状与进展  

Research progress in the application of drug eluting beads transarterial chemoembolization as bridge therapy for hepatocellular carcinoma before liver transplantation

作　　者：王浩[1] 高海军[1] 伊正甲 陈光[1] Wang Hao;Gao Haijun;Yi Zhengjia;Chen Guang(Department of Radiology,Tianjin First Central Hospital,Tianjin 300192,China)

机构地区：[1]天津市第一中心医院放射科,300192

出　　处：《国际生物医学工程杂志》2020年第3期255-258,F0003,共5页International Journal of Biomedical Engineering

摘　　要：肝癌肝移植术前过渡治疗的目的是防止符合肝移植标准的患者等待期间肿瘤进展超过肝移植标准,并将超过肝移植标准的肝癌降期至符合肝移植标准以降低术后肿瘤复发率。传统的经导管动脉内化疗栓塞(cTACE)存在术后全身反应大、对肝功能影响大的缺点。载药微球是一种新型栓塞材料,载药微球化疗栓塞(DEB-TACE)相较于cTACE,可持续稳定地在肿瘤局部释放化疗药物,时间可长达数周,并且血液循环中的药物浓度极低,从而有效避免化疗药物导致的全身反应,在肝癌肝移植术前的过渡治疗中更为高效。对DEB-TACE治疗在肝癌肝移植术前应用的现状与研究进展进行综述。The aims of bridging treatments before liver transplantation is to prevent the tumor from progressing to exceed the liver transplantation standards during the waiting period of patients with hepatocellular carcinoma(HCC),and to downgrade the HCC to meet the liver transplantation standards so as to reduce the postoperative tumor recurrence rate.Conventional transcatheter arterial chemoembolization(cTACE)has the disadvantages of large systemic adverse reactions and great influence on liver function.Drug-eluting beads(DEBs)are a new type of embolization material.Compared with cTACE,DEB-TACE can continuously and stably release chemotherapeutic drugs locally on the tumor for several weeks.Moreover,the concentration of the chemotherapeutic drug in the blood circulation is extremely low,which can effectively avoid systemic reactions caused by chemotherapy drugs,and is more effective in thebridging treatments of liver transplantation.In this paper,the current status and research progress of DEB-TACE treatment before liver transplantation for liver cancer were reviewed.

关 键 词：肝肿瘤 肝移植 栓塞 治疗性 载药微球 

分 类 号：R735.7[医药卫生—肿瘤]